Analyst Ratings For American Renal Associates (NYSE:ARA)
Today, American Renal Associates (NYSE:ARA) stock was downgraded by Leerink Swann from Outperform to Market Perform with a price target of $27.00.
Some recent analyst ratings include
- 3/8/2018-Leerink Swann was Downgraded by analysts at Leerink Swann from a “Outperform ” rating to a ” Market Perform” rating. They now have a $27.00 price target on the stock, up previously from $17.00 .
- 5/11/2017-Wells Fargo & Co Upgrade from a “Market Perform ” rating to a ” Outperform” rating.
- 11/21/2016-Goldman Sachs Group was Downgraded by analysts at Goldman Sachs Group from a “Neutral ” rating to a ” Sell” rating.
- 8/22/2016-Bank of America Reiterated Rating of Buy.
Recent Insider Trading Activity For American Renal Associates (NYSE:ARA)
American Renal Associates (NYSE:ARA) has insider ownership of 12.62% and institutional ownership of 91.64%.
- On 6/9/2017 Jason Allen Ross Brewster, Director, bought 80,000 with an average share price of $0.03 per share and the total transaction amounting to $2,400.00.
- On 4/26/2016 John J Mcdonough, COO, bought 1,000 with an average share price of $22.00 per share and the total transaction amounting to $22,000.00.
- On 4/26/2016 Jonathan L Wilcox, CFO, bought 500 with an average share price of $22.00 per share and the total transaction amounting to $11,000.00.
- On 4/26/2016 Michael Ray Costa, VP, bought 370 with an average share price of $22.00 per share and the total transaction amounting to $8,140.00.
- On 4/2/2015 Meyer (Mike) Frederi Florence, Director, bought 12,000 with an average share price of $0.01 per share and the total transaction amounting to $120.00.
Recent Trading Activity for American Renal Associates (NYSE:ARA)
Shares of American Renal Associates closed the previous trading session at 22.59 down -0.93 3.95% with 21.34000015258789 shares trading hands.